SCYNEXIS is a biotechnology company. Co. is developing its main product candidate, ibrexafungerp, as an intravenous/oral agent for multiple fungal indications in both the community and hospital settings. The U.S. Food and Drug Administration has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis, respectively. Co. is also continuing on-going clinical studies of ibrexafungerp for multiple indications, including the treatment of life-threatening invasive fungal infections in hospitalized patients. The SCYX average annual return since 2014 is shown above.
The Average Annual Return on the SCYX average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SCYX average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SCYX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free SCYX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
